Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres
Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the third quarter ended September 30, 2023. Q3 and Recent Business Highlights Advanced its pipeline programs including ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash) and its Joint Development Agreement with Bayer Completed and filed post-IND, FDA commitments for characterization of drug product for ATR-12 Selected and hired clinical research organization for ATR-12 clinical trial. Selected initial sites for activation Francisco Salva, Chief Executive Officer of Azitra, commented: "During t
BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will
8-K - Azitra, Inc. (0001701478) (Filer)
10-Q - Azitra, Inc. (0001701478) (Filer)
8-K - Azitra, Inc. (0001701478) (Filer)
SC 13D/A - Azitra, Inc. (0001701478) (Subject)
SC 13G - Azitra, Inc. (0001701478) (Subject)
SC 13G - Azitra, Inc. (0001701478) (Subject)
4 - Azitra, Inc. (0001701478) (Issuer)
Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking presentation related to ATR-04. The presentation by Dr. Mary Spellman will take place on Thursday, September 26, 2024, in a late-breaking oral session entitled "Development of a Staphylococcus epidermidis strain for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity" at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam. ATR-04 is a live biotherapeutic product candidate consisting of an S. epidermidis strain that was isolated fro
Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for topically applied ATR-04 to treat moderate to severe Epidermal Growth Factor Receptor inhibitor (EGFRi) associated dermal toxicity. Francisco Salva, Azitra's CEO, stated, "We are thrilled to announce the FDA has granted Fast Track designation to ATR-04, demonstrating that the FDA recognizes the unmet need for treatment of EGFRi-associated skin rash. Many cancer patients receive EGFR inhibitors, which often have significant side effects, resulting in rashes
Azitra, Inc. (NYSE:AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 9-11, 2024. Company management will also be participating in one-on-one meetings during the conference. The on-demand presentation will be available for viewing beginning September 9 at 7:00 a.m. ET. An archived replay of the presentation will be available on the Company's website immediately following the conference and for at least 30 days thereafter. H.C. Wainwright 26th Annual Global Investment Conference – September 9-11, 2024 Format:
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 100 points on Wednesday. The Dow traded down 0.82% to 40,025.48 while the NASDAQ fell 2.92% to 17,472.06. The S&P 500 also fell, dropping, 1.84% to 5,453.67. Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’ Leading and Lagging SectorsUtilities shares jumped by 0.8% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 3%. Top Headline Shares of AT&T Inc. (NYSE:T) rose around 5% during Wednesday’s session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
Azitra Inc. (AMEX:AZTR) shares are crashing Wednesday after the company announced the pricing of a $10 million public offering of 6,665,000 common shares and Class A warrants at $1.50 per share. The Details: Azitra shares spiked Tuesday after the company announced that the U.S. Patent and Trademark Office (USPTO) had granted the company a patent covering future potential pipeline candidates for indications including atopic dermatitis, titled “Therapeutic treatment of skin disease with recombinant skin microorganisms.” Read Next: What’s Going On With Carnival Stock? Azitra announced the pricing of its $10 million public offering after the market close Tuesday. The company said it
4 - Azitra, Inc. (0001701478) (Issuer)